Bad intentions - good policies: Who wins? Case exercise and role play on drug counterfeiting in an LDC context World Bank Case Exercise – all names and.

Slides:



Advertisements
Similar presentations
The Health and Safety Risks Counterfeit products Pose to Consumers Christine HUBER 2 December Cancun.
Advertisements

1Comprehensive Disaster Risk Management Framework National Disaster Management Systems 111 Institutional Arrangements and Organizational Structures Session.
The Global Context Lecture 3 The Global Business Environment.
University of Sunderland / MDIS. » Explain the process of internationalization; » Identify reasons for FDI; » Select target markets and sites for exporting.
Burden of malaria and other infectious diseases in the Asia-Pacific Ravi P. Rannan-Eliya Institute for Health Policy Sri Lanka.
@DiscoverForums DiscoverForums Healthcare in Vietnam Estimated market size US$ 265 mil in 2014 Market growth approximately 12% between
Presentation to the 2014 International AIDS Conference
GS1 standards – advantages and barriers in the produce of medicine Bratislava, 20. September 2007 Peter Vavro Logistics manager, Zentiva, a.s.
Slide 2 Key Points Although HIV/AIDS is found throughout the world, most people living with HIV/AIDS reside in low- and middle-income countries More people.
Government of Tanzania/DFID Partnership Capacity Building.
9/11 “The Malaria epidemic is like loading up seven Boeing 747 airplanes each day then deliberately crashing them into Mt Kilamanjaro” Chairman Malaria.
Health Scenario in Sri Lanka
Subsidized Private Health Insurance in Africa PharmAccess Foundation and Health Insurance Fund Programs Emily Gustafsson-Wright Brookings Institution and.
SAfAIDS,ZAN LEARNING AND SHARING EVENT Feedback from the XVII International AIDS Conference 2008 Emerging Issues in Workplace Programmes.
Tajikistan The Global Fund to Fight AIDS, Tuberculosis and Malaria Support to the Strategic Plan to Prevent HIV/AIDS Epidemics in Tajikistan. November.
Aid for Trade Needs Assessment – Georgia United Nations Development Programme.
The Role of Government in the United States Economy How does the United States government promote and regulate competition?
How to determine medicines benefits policy and program needs?
CLICK TO ADD TITLE THE BAD GUYS AETNA. History / CEO Core Products and Services Bad Guys vs. Good Guys –Strengths, Weaknesses, Financial Performance Recent.
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
Political Economy.
Chapter 26.3 Economies in Transition. The Transition From a Command Economy Today, many nations are changing from one type of economy to another. Some.
The Draft SADC Annex on Trade in Services UNCTAD Secretariat Sub-regional Conference on Improving Industrial Performance and Promoting Employment in SADC.
Mozambique: Political Economy Mozambique: Political Economy Nick Dubaz Naval Postgraduate School Monterey, California.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.
Country Assessment to Determine Factors Influencing the Cost, Availability and Distribution of Acyclovir in Eight Sub-Saharan African Countries Catherine.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Tanzania1. 2 Tanzania Assessment Gabriel Upunda Tanzania3 DemographicsTanzania Area (sq km)945,100 Population 32,900,000 25% urban GNP per capitaUS $240.
Pharmaceutical system strengthening – Is there a need for a new paradigm? Andreas Seiter The World Bank ICIUM 2011, Antalya 1.
Improving Access and Use of Medicines through Private Sector Initiatives: A case for an Essential Medicines Franchise in Ghana Eghan Kwesi, Mensah D, Idun.
‘ There is an increasing recognition that public health often provides and added and compelling justification for safeguarding human rights, despite the.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
1 IASC Weekly meeting Geneva, 14 September 2005 Malaria control in emergency settings Charles Delacollette WHO/Roll Back Malaria Department.
Public and private sector roles in addressing animal health issues Strengthening the relationship between public and private sector roles (commercial and.
Can Competition-Promoting Policies Reduce Medicine Prices in Developing Countries? Loraine Hawkins ICIUM, Track 2c Economics Tuesday, 15 November,
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
CO “All-Ukrainian Network of People Living with HIV” Potential Problems in Supply – What Can Be Done? Kyiv, 2008.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
FIFTH MEETING OF HEALTH TEAM IHP+ COUNTRIES 2 – 5 December 2014, Siem Reap, Cambodia SESSION 7c) Managing Purchasing and Stock in Guinea-Bissau Current.
1 EAST AFRICAN PUBLIC PROCUREMENT – FORUM JUNE 2008 – Procurement Context TOPIC Context of Public Procurement in East Africa and Objectives of this Forum.
UNDP Programming for Avian Influenza. What is the UN doing?
Stop the Stock-outs! Access to Essential Medicines for All Christa Cepuch BSc Phm Health Action International Africa RHS Coalition Meeting 27 May 2010,
Preparing for negotiation  Understand client’s business intention and goals  Measure positioning of your client and the opposite party: the purpose.
Aid for Trade Progress on the Initiative in 2007 and Report on the Mandate to ECA Stephen N. Karingi Chief, Trade and International Negotiations Section,
Video Questions and Answers.  What is your current impression of Africa?  What are some of the natural resources found in Africa?
Procurement & Fiduciary services Department Development Bank African The 1 THE HIGH LEVEL FORUM ON PUBLIC PROCUREMENT REFORMS IN AFRICA Progress, Challenges,
Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action.
Marketing Plan.
Governance in Central and Eastern Europe Cheryl W. Gray Europe and Central Asia Region World Bank.
The Global Drug Gap: Access Inequities and Policy Implications Michael R. Reich Harvard School of Public Health International Conference on Pharmacoepidemiology.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Globalization: Costs and Benefits DR. Amjad Fathi El-Shanti MD,NPH,DR PH University of Palestine 2016.
Australia’s aid for trade approaches Presentation by Henni Arup Multilateral Aid for Trade Section Department of Foreign Affairs and Trade.
The Czech Health System – its Presence and Future
Economics and the Global Economy
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Goal 8 Develop a global partnership for development
The Cost of Prescriptions
Preparing for Negotiation & Drafting Business Contracts
Business in Partnership Against Corruption
Medicine in third world countries
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
Labour Markets: Security and Social Protection in the Informal Sector Complementary Comments by Johannes Jütting Development Centre, OECD, Paris.
Chapter 2 The Economics and the Global Economy
Formalizing the Informal Economy: A Gender Perspective Thailand
Accredited Drug Dispensing Outlets (ADDOs): Improving Access to Quality Drugs and Services in Rural and Peri-urban Areas with Few.
Expert Speak: How Pharma Companies Can Grow Their Business?
Presentation transcript:

Bad intentions - good policies: Who wins? Case exercise and role play on drug counterfeiting in an LDC context World Bank Case Exercise – all names and characters are fictional, possible similarities with living persons or existing businesses would be unintentional

Republic of Buwani, Central Africa Ngorone Kuwabashi Seronego Posi MfanaAluna Kaluni River 255,000 sqm 18 million inhabitants GDP per capita USD 385

Key Facts A typical young African democracy History of postcolonial civil war But now stable for almost 10 years Low Income Country, 4% growth 35% urban/suburban population 18% wealthy, 42% very poor

Healthcare System Majority gets care in the private sector Public clinics/hospitals reach 15-20% Cash-and carry system Community insurance funds, covering 30% of Posi people Malaria health priority #1 HIV infection rate estimated at 7%

Pharmaceutical Supplies Public CMS – PMS system, yearly planning Typical weaknesses: Corruption, stock-outs. Leading to under-utilization of public providers. Lively private sector market for medicines, through pharmacies and street sellers. Prescription drugs can be purchased without prescription. Usually good quality of drugs in public sector No data on counterfeits, but anecdotal reports

Law and Regulation Food and Drug law, regulatory approval system, but illegal imports are possible Limited enforcement capacity, inspectors spend most of their time checking imported drugs at customs. No serious punishment for selling non- registered drugs or violating trademarks. No special legal provision dealing with counterfeit drugs

Donor Support for Malaria World Bank and Global Fund provide USD 15 million Education, prevention, treatment Switch of first line therapy from chloroquine to artemisinin combination (ACT)

The Counterfeiters Patrick Kafomo, rich businessman and owner of an “ informal ” trade empire History as arms dealer, now in “ branded ” textiles and luxury goods, cosmetics etc. Works through network of informal sellers Invests in good relationships with officials Owns a private security force Get an offer to build a counterfeit drug business, based on new treatment guidelines

The Government / MOH Knows that 80% of malaria treatment is in the private sector Has to introduce ACT treatment Gets financial support to cover increased procurement costs and implement information campaign Needs to secure the distribution chain to prevent counterfeits from entering

Questions to Answer – Bad Guys Are counterfeit drugs good business? What resources are needed to develop this business? What are strengths and weaknesses of the counterfeiter ’ s operation? How can the business risk be managed?

Questions to Answer – Good Guys Will counterfeits become reality? Who will be affected? What is your defense strategy? What are the obstacles you are facing and how do you address them? What resources do you need? How long will it take?

Logistics Breakout Groups 6-8 participants Breakout rooms 3d/4 th floor Use flipchart for discussion No presentations required Facilitated discussion based on your answers to the questions Please be back at 12:00 for box lunch Meeting resumes at 1:00 pm sharp